Publications

Peer-Reviewed Original Research Articles

1. Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DW, Gathe JC, Visnegarwala F, Trautner BW. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 81(3):213-27, 5/2002.
2. Shelburne SA, Hamill RJ. The immune reconstitution inflammatory syndrome. AIDS Rev 5(2):67-79, Apr-Jun, 4/2003.
3. Shelburne SA, Kielhofner MA, Tiwari PS. Cerebellar involvement in legionellosis. South Med J 97(1):61-4, 1/2004.
4. Shelburne SA, Musser JM. Virulence gene expression in vivo. Curr Opin Microbiol 7(3):283-9, 6/2004.
5. Shelburne SA, Musher DM, Hulten K, Ceasar H, Lu MY, Bhaila I, Hamill RJ. In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations. Antimicrob Agents Chemother 48(10):4016-9, 10/2004. PMCID: PMC521878.
6. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC, Hamill RJ. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 19(4):399-406, 3/2005.
7. Shelburne SA, Darcourt J, White AC, Greenberg SB, Hamill RJ, Atmar RL, Visnegarwala F. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 40(7):1049-52, 4/2005.
8. Shelburne SA, Granville C, Tokuyama M, Sitkiewicz I, Patel P, Musser JM. Growth characteristics of and virulence factor production by group A Streptococcus during cultivation in human saliva. Infect Immun 73(8):4723-31, 8/2005. PMCID: PMC1201272.
9. Shelburne SA, Visnegarwala F, Adams C, Krause KL, Hamill RJ, White AC. Unusual manifestations of disseminated Histoplasmosis in patients responding to antiretroviral therapy. Am J Med 118(9):1038-41, 9/2005.
10. Shelburne SA, Sumby P, Sitkiewicz I, Granville C, DeLeo FR, Musser JM. Central role of a bacterial two-component gene regulatory system of previously unknown function in pathogen persistence in human saliva. Proc Natl Acad Sci U S A 102(44):16037-42, 11/2005. PMCID: PMC1276065.
11. Kaka AS, Rueda AM, Shelburne SA, Hulten K, Hamill RJ, Musher DM. Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 58(3):680-3, 9/2006.
12. Gonzalez BE, Rueda AM, Shelburne SA, Musher DM, Hamill RJ, Hulten KG. Community-associated strains of methicillin-resistant Staphylococcus aureus as the cause of healthcare-associated infection. Infect Control Hosp Epidemiol 27(10):1051-6, 10/2006.
13. Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 57(2):167-70, 2006.
14. Shelburne SA, Sumby P, Sitkiewicz I, Okorafor N, Granville C, Patel P, Voyich J, Hull R, DeLeo FR, Musser JM. Maltodextrin utilization plays a key role in the ability of group A Streptococcus to colonize the oropharynx. Infect Immun 74(8):4605-14, 2006. PMCID: PMC1539623.
15. Shelburne SA, Greenberg SB, Aslam S, Tweardy DJ. Successful ceftriaxone therapy of endocarditis due to penicillin non-susceptible viridans streptococci. J Infect 54(2):e99-101, 2/2007.
16. Shelburne SA, Fang H, Okorafor N, Sumby P, Sitkiewicz I, Keith D, Patel P, Austin C, Graviss EA, Musser JM, Chow DC. MalE of group A Streptococcus participates in the rapid transport of maltotriose and longer maltodextrins. J Bacteriol 189(7):2610-7, 4/2007. e-Pub 1/2007. PMCID: PMC1855798.
17. Daver NG, Shelburne SA, Atmar RL, Giordano TP, Stager CE, Reitman CA, White AC. Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. J Infect 54(6):539-44, 6/2007.
18. Shelburne SA, Okorafor N, Sitkiewicz I, Sumby P, Keith D, Patel P, Austin C, Graviss EA, Musser JM. Regulation of polysaccharide utilization contributes to the persistence of group a streptococcus in the oropharynx. Infect Immun 75(6):2981-90, 6/2007. PMCID: PMC1932865.
19. Shelburne SA, Singh KV, White AC, Byrne L, Carmer A, Austin C, Graviss E, Stager C, Murray BE, Atmar RL. Sequential outbreaks of infections by distinct Acinetobacter baumannii strains in a public teaching hospital in Houston, Texas. J Clin Microbiol 46(1):198-205, 1/2008. PMCID: PMC2224270.
20. Shelburne SA, Keith D, Horstmann N, Sumby P, Davenport MT, Graviss EA, Brennan RG, Musser JM. A direct link between carbohydrate utilization and virulence in the major human pathogen group A Streptococcus. Proc Natl Acad Sci U S A 105(5):1698-1703, 2/2008. PMCID: PMC2234207.
21. Shelburne SA, Keith DB, Davenport MT, Horstmann N, Brennan RG, Musser JM. Molecular characterization of group A Streptococcus maltodextrin catabolism and its role in pharyngitis. Mol Microbiol 69(2):436-52, 7/2008.
22. Shelburne SA 3rd, Davenport M, Keith D, Musser JM. The role of complex carbohydrate metabolism in the pathogenesis of invasive streptococci. Trends Microbiol 16(7):318-25, 7/2008.
23. Livorsi DJ, Daver NG, Atmar RL, Shelburne SA, White AC, Musher DM. Outcomes of treatment for hematogenous Staphylococcus aureus vertebral osteomyelitis in the MRSA ERA. J Infect 57(2):128-31, 8/2008.
24. Olsen RJ, Shelburne SA, Musser JM. Molecular mechanisms underlying group A streptococcal pathogenesis. Cell Microbiol 11(1):1-12, 1/2009.
25. Safdar A, Shelburne SA, Evans SE, Dickey BF. Inhaled therapeutics for prevention and treatment of pneumonia. Expert Opin Drug Saf 8(4):435-49, 7/2009.
26. Treviño J, Perez N, Ramirez-Peña E, Liu Z, Shelburne SA, Musser JM, Sumby P. CovS simultaneously activates and inhibits the CovR-mediated repression of distinct subsets of group A Streptococcus virulence factor-encoding genes. Infect Immun 77(8):3141-9, 8/2009. PMCID: PMC2715666.
27. Musser JM, Shelburne SA. A decade of molecular pathogenomic analysis of group A Streptococcus. J Clin Invest 119(9):2455-63, 9/2009. PMCID: PMC2735924.
28. Shelburne SA, Keith DB, Davenport MT, Beres SB, Carroll RK, Musser JM. Contribution of AmyA, an extracellular alpha-glucan degrading enzyme, to group A streptococcal host-pathogen interaction. Mol Microbiol 74(1):159-74, 10/2009.
29. Shelburne SA, Olsen RJ, Suber B, Sahasrabhojane P, Sumby P, Brennan RG, Musser JM. A combination of independent transcriptional regulators shapes bacterial virulence gene expression during infection. PLoS Pathog 6(3):e1000817, 3/2010. PMCID: PMC2841617.
30. Kung DH, Hubenthal EA, Kwan JY, Shelburne SA, Goodman JC, Kass JS. Toxoplasmosis myelopathy and myopathy in an AIDS patient: a case of immune reconstitution inflammatory syndrome? Neurologist 17(1):49-51, 1/2011.
31. Carroll RK, Shelburne SA, Olsen RJ, Suber B, Sahasrabhojane P, Kumaraswami M, Beres SB, Shea PR, Flores AR, Musser JM. Naturally occurring single amino acid replacements in a regulatory protein alter streptococcal gene expression and virulence in mice. J Clin Invest 121(5):1956-68, 5/2011. PMCID: PMC3083769.
32. Shelburne SA, Sahasrobhajane P, Suber B, Keith DB, Davenport MT, Horstmann N, Kumaraswami M, Olsen RJ, Brennan RG, Musser JM. Niche-specific contribution to streptococcal virulence of a MalR-regulated carbohydrate binding protein. Mol Microbiol 81(2):500-14, 7/2011. PMCID: PMC3147245.
33. Horstmann N, Sahasrabhojane P, Suber B, Kumaraswami M, Olsen RJ, Flores A, Musser JM, Brennan RG, Shelburne SA. Distinct single amino acid replacements in the control of virulence regulator protein differentially impact streptococcal pathogenesis. PLoS Pathog 7(10):e1002311, 10/2011. PMCID: PMC3197619.
34. Shelburne SA, Olsen RJ, Makthal N, Brown NG, Sahasrabhojane P, Watkins EM, Palzkill T, Musser JM, Kumaraswami M. An N-Terminal Signal Peptide Of Vfr Protein Negatively Influences RopB-Dependent SpeB Expression and Attenuates Virulence in Streptococcus pyogenes. Mol Microbiol 82(6):1481-95, 12/2011.
35. Lin E, Bhusal Y, Horwitz D, Shelburne SA, Trautner BW. Overtreatment of enterococcal bacteriuria. Arch Intern Med 172(1):33-8, 1/2012.
36. Olsen RJ, Laucirica DR, Watkins ME, Feske ML, Garcia-Bustillos JR, Vu C, Cantu C, Shelburne SA, Fittipaldi N, Kumaraswami M, Shea PR, Flores AR, Beres SB, Lovgren M, Tyrrell GJ, Efstratiou A, Low DE, Van Beneden CA, Musser JM. Polymorphisms in Regulator of Protease B (RopB) Alter Disease Phenotype and Strain Virulence of Serotype M3 Group A Streptococcus. J Infect Dis 205(11):1719-29, 6/2012.
37. Shelburne SA, Tarrand J, Rolston KV. Review of streptococcal bloodstream infections at a comprehensive cancer care center, 2000-2011. J Infect. e-Pub 11/2012.
38. Horstmann N, Orans J, Valentin-Hansen P, Shelburne SA, Brennan RG. Structural mechanism of Staphylococcus aureus Hfq binding to an RNA A-tract. Nucleic Acids Res 10, 2012.
39. Anthony R. Flores, Pranoti Sahasrabhojane, Miguel Saldaña, Jessica Galloway-Peña, Randall J. Olsen, James M. Musser, and Samuel A. Shelburne. Molecular Characterization of an Invasive Phenotype of Group A Streptococcus Arising During Human Infection Using Whole Genome Sequencing of Multiple Isolates From the Same Patient. J Infect Dis, 12/2013.
40. Flores AR, Olsen RJ, Wunsche A, Kumaraswami M, Shelburne SA 3rd, Carroll RK, Musser JM. Natural variation in the promoter of the gene encoding the Mga regulator alters host-pathogen interaction in group A Streptococcus carrier strains. Infect Immun, 2013.
41. Sahasrabhojane P, Galloway-Peña J, Velazquez L, Saldaña M, Horstmann N, Tarrand J, Shelburne SA. Species Level Assessment of the Molecular Basis of Fluoroquinolone Resistance Among Viridans Group Streptococci Causing Bacteremia in Cancer Patients. Int J Antimicrob Agents(IJAA-D-13-01032R1), 3/2014.
42. Shelburne SA, Lasky R, Sahasrabhojane P, Tarrand JR; Rolston KV. Development and Validation of a Clinical Model to Predict the Presence of β-lactam Resistance in Viridans Group Streptococci Causing Bacteremia in Neutropenic Cancer Patients. Clin Infect Dis, 4/2014.
43. Aline El Zakhem, Anne-Marie Chaftari, Ramez Bahu, Gilbert El Helou, Samuel Shelburne, Ying Jiang, Ray Hachem, and Issam Raad. Central Line-Associated Bloodstream Infections Caused by Staphylococcus aureus in Cancer Patients: Clinical Outcome and Management. Annals of Medicine 46(3):163-8, 5/2014.
44. N Horstmann, M Saldaña, P Sahasrabhojane, H Yao, X Su, E Thompson, A Koller, and SA Shelburne. Dual-Site Phosphorylation of the Control of Virulence Regulator Impacts Group A Streptococcal Global Gene Expression and Pathogenesis. PLoS Pathogens 1; 10(5):e1004088, 5/2014.
45. Shelburne SA, Sahasrabhojane P, Saldana M, Yao H, Su X, Horstmann N, Thompson E, and Flores AR. Identification and Characterization of Streptococcus mitis Strains Causing Severe Clinical Disease in Cancer Patients. Emerg Infect Dis 5(20):762-71, 5/2014.
46. Jessica Galloway-Peña, Pranoti Sahasrabhojane, Jeffrey Tarrand , Xiang Y. Han, and Samuel A. Shelburne. GyrB Polymorphisms Accurately Assign Invasive Viridans Group Streptococcal Species. J Clin Micro(pii: JCM.01068-14.), http://www.ncbi.nlm.nih.gov/pubmed/24899021#, 6/2014.
47. Flores AR, Jewell BE, Olsen RJ.  Asymptomatic Carriage of Group A Streptococcus is Associated with Elimination of Capsule Production. Infect Immun. 2014 Sep; 82(9):3958-67.
48. Shelburne SA 3rd, Chaftari AM, JamalM, Al Wohoush I, Jiang Y, Abughazaleh S, Cairo J, Raad S, Debiane L, Raad I. Identification and Characterization of Catheter-related Bloodstream Infections Due to Viridans Group Streptococci in Patients with Cancer. Am J. Infect Control. 2014 Oct: 42 (10):1127-9.
49. Holland T., Fowler VG Jr., Shelburne SA 3rd. Invasive Gram-positive Bacterial Infection in Cancer Patients. Clin Infect Dis. 2014 Nov 15:59 Suppl 5:S331-4.
50. Shelburne SA 3rd, Fittipaldi N, Beres SB, Musser JM.Shelburne SA, Ajami NJ, Chibucos MC, Beird HC, Tarrand J, Galloway-Peña J, Albert N, Chemaly RF, Ghantoji SS, Marsh L, Pemmaraju N, Andreeff M, Shpall EJ, Wargo JA, Rezvani K, Alousi A, Bruno VM, Futreal PA, Petrosino JF, Kontoyiannis DP. Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormysocis. PLoS One. 2015 Nov 10;10(11):e0139851.